An interventional study of Sperstent® peripheral spot stent system and Everflex® self-expanding peripheral stent system in Peripheral Arterial Disease, Stenosis and Dissection, sponsored by FrontAce Scientific Co., Ltd. Recruiting at 12 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by FrontAce Scientific Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.
Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 13th largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2024, is one of 34 with no phase, reaches primary completion later than 16 of the 33 other live ones, and was the 63rd registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–100 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
Sirius Therapeutics Co., Ltd. · Sites in China
Ages 18–75
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 1
First in 2008; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 167 across the 53 interventional studies, 254 across the 27 observational. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 80 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with FrontAce Scientific Co., Ltd as lead sponsor.
FrontAce Scientific Co., Ltd has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Arterial Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
| NCT07397390The First Affiliated Hospital of Dalian Medical Universityan Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vessel Preparation Facilitated by IVUS on the Lower Limb Ischemia Patients With Calcified Lesions | 2026-12-30 |
| NCT07602634Zhijun BaoRadiomics Features Predicting Outcomes of PAD | 2026-12-31 |
| NCT03791970Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityStents Post-dilation With DCB or POBA in Femoropopliteal Arteries | 2026-12-31 |
| NCT07860138Fudan UniversityHemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 80 studies in Peripheral Arterial Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and/or dissections in femoral and proximal popliteal arteries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Angiographic Inclusion Criteria:
Exclusion Criteria:
Angiographic Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects using the Sperstent® peripheral spot stent system
Device: Sperstent® peripheral spot stent system
subjects using the Everflex® self-expanding peripheral stent system
Device: Everflex® self-expanding peripheral stent system
Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography(DSA)
Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography(DSA)
Primary Patency
Primary patency defined as freedom from clinically driven target lesion revascularization (CD-TLR) and freedom from duplex ultrasound derived binary restenosis at 12 months post-operation.(defined as PSVR \>2.5)
Time frame: 12 months post-operation
Freedom from Major Adverse Events (MAEs)
Freedom from the occurrence of any new-onset MAEs defined as all-cause death, index limb amputation (above the ankle), or clinically-driven target lesion revascularization (CD-TLR) at 30 days post-operation.
Time frame: 30 days post-operation
Rate of Device Success
Defined as successful delivery, release and retrieval of the device.
Time frame: immediately post-operation
Rate of Procedural Success
Demonstrated vessel patency (\<30% residual DS, by visual estimate) without the use of a bailout stent or the occurrence of MAE upon completion of the index procedure.
Time frame: immediately post-operation
Primary Patency at 30 days and 6 months
defined as freedom from clinically driven target lesion revascularization (CD-TLR) and freedom from duplex ultrasound derived binary restenosis at 30 days and 6 months post-operation (defined as PSVR \>2.5)
Time frame: 30 days and 6 months post-operation
Rate of clinically driven target lesion revascularization (CD-TLR)
Clinically driven target lesion revascularization (CD-TLR) was defined as an endovascular reintervention performed for a \>50% diameter stenosis of the target vessel in the presence of a recurrent PAD symptom after the initial endovascular procedure.
Time frame: 30 days, 6 months and 12 months post-operation
Changes from Baseline in Rutherford Classification
Defined as change in target limb Rutherford class from baseline. Rutherford Classification is defined as follows, with increasing severity: Rutherford Category 0 - Asymptomatic. Rutherford Category 1 - Mild Claudication. Rutherford Category 2 - Moderate Claudication. Rutherford Category 3 - Severe Claudication. Rutherford Category 4 - Ischemic Rest Pain. Rutherford Category 5 - Minor Tissue Loss (minor exertion). Rutherford Category 6 - Major Tissue Loss (gangrene).
Time frame: 30 days, 6 months and 12 months post-operation
Changes from Baseline in Ankle-brachial Index (ABI)
Defined as change of target limb ABI from baseline. The Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm.
Time frame: 30 days, 6 months and 12 months post-operation
Duplex Ultrasound (DUS) Derived Lesion Patency
Lesion Patency is evaluated by Duplex Ultrasound (DUS)
Time frame: 30 days, 6 months and 12 months post-operation
Rate of major adverse event(s) (MAEs)
MAEs defined as all-cause death, index limb amputation (above the ankle), or clinically-driven target lesion revascularization (CD-TLR) .
Time frame: 6 months and 12 months post-operation
Rate of Stent Fracture
Stent fractures will be analyzed by X-ray at 12 months post-operation. The stents implanted into a certain subject will be analyzed collectively in the assessment. Stent fractures will be assessed with Grade I, II, III or IV as follow. Grade I - a single strut fracture only. Grade II - multiple single strut fractures that occur at different sites of a stent or different stents. Grade III - multiple nitinol stent fractures resulting in complete transverse linear fracture. Grade IV - a spiral dissection of a stent. Fractures of Grade I are least severe, increasing in severity to Grade IV.
Time frame: 12 months post-operation
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 30 months is close to that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.